Common Contracts
44 similar Executive Employment Agreement contracts by Syndax Pharmaceuticals Inc, Kezar Life Sciences, Inc., Immune Design Corp.
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 18th, 2024 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations • New York
Executive Officer; (E) this Release shall not be effective until the date upon which the revocation period has expired, which shall be the eighth day (8th) after I execute this Release; and (F) I have received with this Release the required written disclosure for a “group termination” under the ADEA, including a detailed list of the job titles and ages of all employees who were terminated in this group termination and the ages of all employees of the Company in the same job classification or organizational unit who were not terminated.
AMENDED & RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • February 27th, 2024 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations • New York
This AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of the 27th day of April, 2020 (the “Effective Date”), between LUKE J. ALBRECHT (“Executive”) and SYNDAX PHARMACEUTICALS, INC. (the “Company”). Certain capitalized terms used in this Agreement are defined in Article 6.
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • November 13th, 2023 • Kezar Life Sciences, Inc. • Pharmaceutical preparations • California
This EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is effective as of November 7, 2023 (the “Effective Date”), between Christopher J. Kirk, Ph.D. (“Executive”) and KEZAR LIFE SCIENCES, INC. (the “Company”). Certain capitalized terms used in this Agreement are defined in Article 7.
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 30th, 2023 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations • New York
Executive Officer; (E) this Release shall not be effective until the date upon which the revocation period has expired, which shall be the eighth day (8th) after I execute this Release; and (F) I have received with this Release the required written disclosure for a “group termination” under the ADEA, including a detailed list of the job titles and ages of all employees who were terminated in this group termination and the ages of all employees of the Company in the same job classification or organizational unit who were not terminated.
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • December 5th, 2022 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations • New York
Executive Officer; (E) this Release shall not be effective until the date upon which the revocation period has expired, which shall be the eighth day (8th) after I execute this Release; and (F) I have received with this Release the required written disclosure for a “group termination” under the ADEA, including a detailed list of the job titles and ages of all employees who were terminated in this group termination and the ages of all employees of the Company in the same job classification or organizational unit who were not terminated.
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • June 13th, 2022 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations • New York
Executive Officer; (E) this Release shall not be effective until the date upon which the revocation period has expired, which shall be the eighth day (8th) after I execute this Release; and (F) I have received with this Release the required written disclosure for a “group termination” under the ADEA, including a detailed list of the job titles and ages of all employees who were terminated in this group termination and the ages of all employees of the Company in the same job classification or organizational unit who were not terminated.
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 9th, 2022 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations • New York
Executive Officer; (E) this Release shall not be effective until the date upon which the revocation period has expired, which shall be the eighth day (8th) after I execute this Release; and (F) I have received with this Release the required written disclosure for a “group termination” under the ADEA, including a detailed list of the job titles and ages of all employees who were terminated in this group termination and the ages of all employees of the Company in the same job classification or organizational unit who were not terminated.
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 9th, 2022 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations • New York
Executive Officer; (E) this Release shall not be effective until the date upon which the revocation period has expired, which shall be the eighth day (8th) after I execute this Release; and (F) I have received with this Release the required written disclosure for a “group termination” under the ADEA, including a detailed list of the job titles and ages of all employees who were terminated in this group termination and the ages of all employees of the Company in the same job classification or organizational unit who were not terminated.
AMENDED & RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 1st, 2022 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations • New York
earlier); (D) I have seven (7) days following my execution of this Release to revoke the Release by providing a written notice of revocation to the Company’s Chief Executive Officer; (E) this Release shall not be effective until the date upon which the revocation period has expired, which shall be the eighth day (8th) after I execute this Release; and (F) I have received with this Release the required written disclosure for a “group termination” under the ADEA, including a detailed list of the job titles and ages of all employees who were terminated in this group termination and the ages of all employees of the Company in the same job classification or organizational unit who were not terminated.
AMENDED & RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 1st, 2022 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations • New York
of revocation to the Company’s Chief Executive Officer; (E) this Release shall not be effective until the date upon which the revocation period has expired, which shall be the eighth day (8th) after I execute this Release; and (F) I have received with this Release the required written disclosure for a “group termination” under the ADEA, including a detailed list of the job titles and ages of all employees who were terminated in this group termination and the ages of all employees of the Company in the same job classification or organizational unit who were not terminated.
AMENDED & RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • February 3rd, 2022 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations • New York
of revocation to the Company’s Chief Executive Officer; (E) this Release shall not be effective until the date upon which the revocation period has expired, which shall be the eighth day (8th) after I execute this Release; and (F) I have received with this Release the required written disclosure for a “group termination” under the ADEA, including a detailed list of the job titles and ages of all employees who were terminated in this group termination and the ages of all employees of the Company in the same job classification or organizational unit who were not terminated.
AMENDED & RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • February 3rd, 2022 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations • New York
earlier); (D) I have seven (7) days following my execution of this Release to revoke the Release by providing a written notice of revocation to the Company’s Chief Executive Officer; (E) this Release shall not be effective until the date upon which the revocation period has expired, which shall be the eighth day (8th) after I execute this Release; and (F) I have received with this Release the required written disclosure for a “group termination” under the ADEA, including a detailed list of the job titles and ages of all employees who were terminated in this group termination and the ages of all employees of the Company in the same job classification or organizational unit who were not terminated.
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • November 5th, 2020 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations • New York
Executive Officer; (E) this Release shall not be effective until the date upon which the revocation period has expired, which shall be the eighth day (8th) after I execute this Release; and (F) I have received with this Release the required written disclosure for a “group termination” under the ADEA, including a detailed list of the job titles and ages of all employees who were terminated in this group termination and the ages of all employees of the Company in the same job classification or organizational unit who were not terminated.
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 7th, 2020 • Kezar Life Sciences, Inc. • Pharmaceutical preparations • California
have forty-five (45) days to consider this Release (although I may choose to voluntarily execute this Release earlier); (D) I have seven (7) days following my execution of this Release to revoke the Release by providing a written notice of revocation to the Company’s Chief Executive Officer; (E) this Release shall not be effective until the date upon which the revocation period has expired, which shall be the eighth day (8th) after I execute this Release; and (F) I have received with this Release the required written disclosure for a “group termination” under the ADEA, including a detailed list of the job titles and ages of all employees who were terminated in this group termination and the ages of all employees of the Company in the same job classification or organizational unit who were not terminated.
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 7th, 2020 • Kezar Life Sciences, Inc. • Pharmaceutical preparations • California
have forty-five (45) days to consider this Release (although I may choose to voluntarily execute this Release earlier); (D) I have seven (7) days following my execution of this Release to revoke the Release by providing a written notice of revocation to the Company’s Chief Executive Officer; (E) this Release shall not be effective until the date upon which the revocation period has expired, which shall be the eighth day (8th) after I execute this Release; and (F) I have received with this Release the required written disclosure for a “group termination” under the ADEA, including a detailed list of the job titles and ages of all employees who were terminated in this group termination and the ages of all employees of the Company in the same job classification or organizational unit who were not terminated.
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 7th, 2020 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations • New York
of revocation to the Company’s Chief Executive Officer; (E) this Release shall not be effective until the date upon which the revocation period has expired, which shall be the eighth day (8th) after I execute this Release; and (F) I have received with this Release the required written disclosure for a “group termination” under the ADEA, including a detailed list of the job titles and ages of all employees who were terminated in this group termination and the ages of all employees of the Company in the same job classification or organizational unit who were not terminated.
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 7th, 2020 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations • New York
of revocation to the Company’s Chief Executive Officer; (E) this Release shall not be effective until the date upon which the revocation period has expired, which shall be the eighth day (8th) after I execute this Release; and (F) I have received with this Release the required written disclosure for a “group termination” under the ADEA, including a detailed list of the job titles and ages of all employees who were terminated in this group termination and the ages of all employees of the Company in the same job classification or organizational unit who were not terminated.
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 7th, 2020 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations • New York
earlier); (D) I have seven (7) days following my execution of this Release to revoke the Release by providing a written notice of revocation to the Company’s Chief Executive Officer; (E) this Release shall not be effective until the date upon which the revocation period has expired, which shall be the eighth day (8th) after I execute this Release; and (F) I have received with this Release the required written disclosure for a “group termination” under the ADEA, including a detailed list of the job titles and ages of all employees who were terminated in this group termination and the ages of all employees of the Company in the same job classification or organizational unit who were not terminated.
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 7th, 2020 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations • New York
Executive Officer; (E) this Release shall not be effective until the date upon which the revocation period has expired, which shall be the eighth day (8th) after I execute this Release; and (F) I have received with this Release the required written disclosure for a “group termination” under the ADEA, including a detailed list of the job titles and ages of all employees who were terminated in this group termination and the ages of all employees of the Company in the same job classification or organizational unit who were not terminated.
EX-10.8 10 d698822dex108.htm EX-10.8 EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 5th, 2020 • Delaware
This EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of the 20th day of June, 2014 (the “Effective Date”), between Carlos Paya, M.D., Ph.D. (“Executive”) and IMMUNE DESIGN CORP. (the “Company”). Certain capitalized terms used in this Agreement are defined in Article 7.
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 12th, 2020 • Kezar Life Sciences, Inc. • Pharmaceutical preparations • California
have forty-five (45) days to consider this Release (although I may choose to voluntarily execute this Release earlier); (D) I have seven (7) days following my execution of this Release to revoke the Release by providing a written notice of revocation to the Company’s Chief Executive Officer; (E) this Release shall not be effective until the date upon which the revocation period has expired, which shall be the eighth day (8th) after I execute this Release; and (F) I have received with this Release the required written disclosure for a “group termination” under the ADEA, including a detailed list of the job titles and ages of all employees who were terminated in this group termination and the ages of all employees of the Company in the same job classification or organizational unit who were not terminated.
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 7th, 2019 • Kezar Life Sciences, Inc. • Pharmaceutical preparations • California
execute this Release; (B) I have the right to consult with an attorney prior to executing this Release; (C) I have forty-five (45) days to consider this Release (although I may choose to voluntarily execute this Release earlier); (D) I have seven (7) days following my execution of this Release to revoke the Release by providing a written notice of revocation to the Company’s Chief Executive Officer; (E) this Release shall not be effective until the date upon which the revocation period has expired, which shall be the eighth day (8th) after I execute this Release; and (F) I have received with this Release the required written disclosure for a “group termination” under the ADEA, including a detailed list of the job titles and ages of all employees who were terminated in this group termination and the ages of all employees of the Company in the same job classification or organizational unit who were not terminated.
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • June 8th, 2018 • Kezar Life Sciences, Inc. • Pharmaceutical preparations • California
execute this Release; (B) I have the right to consult with an attorney prior to executing this Release; (C) I have forty-five (45) days to consider this Release (although I may choose to voluntarily execute this Release earlier); (D) I have seven (7) days following my execution of this Release to revoke the Release by providing a written notice of revocation to the Company’s President; (E) this Release shall not be effective until the date upon which the revocation period has expired, which shall be the eighth day (8th) after I execute this Release; and (F) I have received with this Release the required written disclosure for a “group termination” under the ADEA, including a detailed list of the job titles and ages of all employees who were terminated in this group termination and the ages of all employees of the Company in the same job classification or organizational unit who were not terminated.
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • June 8th, 2018 • Kezar Life Sciences, Inc. • Pharmaceutical preparations • California
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • August 10th, 2017 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations • New York
revocation to the Company’s Chief Executive Officer; (E) this Release shall not be effective until the date upon which the revocation period has expired, which shall be the eighth day (8th) after I execute this Release; and (F) I have received with this Release the required written disclosure for a “group termination” under the ADEA, including a detailed list of the job titles and ages of all employees who were terminated in this group termination and the ages of all employees of the Company in the same job classification or organizational unit who were not terminated.
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • November 9th, 2016 • Immune Design Corp. • Pharmaceutical preparations • Delaware
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • February 22nd, 2016 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations • New York
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • February 10th, 2016 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations • New York
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • January 4th, 2016 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations • New York
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • January 4th, 2016 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations • New York
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • October 2nd, 2015 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations • New York
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • October 2nd, 2015 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations • New York
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • June 23rd, 2014 • Immune Design Corp. • Pharmaceutical preparations • Delaware
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • June 23rd, 2014 • Immune Design Corp. • Pharmaceutical preparations • Delaware
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • June 23rd, 2014 • Immune Design Corp. • Pharmaceutical preparations • Delaware
